Key Points
- AxoGen Director Joseph Tyndall sold 3,500 shares at an average price of $49.70, totaling $173,950, under a pre-arranged Rule 10b5-1 trading plan. He retained 10,650 shares after the transaction.
- AxoGen shares opened at $48.28 and were up 2.5%, while the company reported quarterly revenue of $69.73 million and adjusted earnings of $0.12 per share, matching analyst expectations on EPS and exceeding revenue estimates.
- Analysts remain broadly positive, with 10 Buy ratings, one Hold, and one Sell; the consensus rating is “Moderate Buy” with a $51.56 price target. Institutional investors own approximately 80.29% of the company.
AxoGen, Inc. (NASDAQ:AXGN - Get Free Report) Director Joseph Tyndall sold 3,500 shares of the company's stock in a transaction that occurred on Wednesday, September 2nd. The stock was sold at an average price of $49.70, for a total value of $173,950.00. Following the transaction, the director owned 10,650 shares of the company's stock, valued at approximately $529,305. This trade represents a 24.73% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
AxoGen Trading Up 2.5%
Shares of AxoGen stock opened at $48.28 on Friday. The company's fifty day simple moving average is $45.21 and its 200-day simple moving average is $40.05. The company has a market cap of $2.60 billion, a price-to-earnings ratio of -71.00 and a beta of 1.16. The company has a current ratio of 6.60, a quick ratio of 5.04 and a debt-to-equity ratio of 0.07. AxoGen, Inc. has a 1 year low of $15.27 and a 1 year high of $52.91.
AxoGen (NASDAQ:AXGN - Get Free Report) last announced its earnings results on Wednesday, July 29th. The medical equipment provider reported $0.12 earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of $0.12. The business had revenue of $69.73 million for the quarter, compared to analyst estimates of $67.10 million. AxoGen had a negative net margin of 13.36% and a negative return on equity of 8.90%. As a group, sell-side analysts expect that AxoGen, Inc. will post -0.45 EPS for the current year.
Analyst Ratings Changes
AXGN has been the topic of several research reports. Citigroup restated a "market outperform" rating on shares of AxoGen in a report on Thursday, July 30th. HC Wainwright increased their target price on shares of AxoGen from $50.00 to $53.00 and gave the company a "buy" rating in a research note on Thursday, July 30th. Canaccord Genuity Group lifted their target price on AxoGen from $50.00 to $55.00 and gave the stock a "buy" rating in a research report on Thursday, July 30th. Zacks Research upgraded AxoGen from a "strong sell" rating to a "hold" rating in a research note on Friday, May 29th. Finally, Truist Financial began coverage on AxoGen in a report on Wednesday, August 26th. They issued a "buy" rating and a $60.00 price target for the company. Ten equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $51.56.
Get Our Latest Research Report on AxoGen
Institutional Investors Weigh In On AxoGen
Institutional investors have recently bought and sold shares of the business. MCF Advisors LLC bought a new stake in AxoGen in the 4th quarter valued at $30,000. Nykredit A S bought a new position in shares of AxoGen during the 2nd quarter worth about $30,000. Aquatic Capital Management LLC lifted its holdings in shares of AxoGen by 287.8% during the 3rd quarter. Aquatic Capital Management LLC now owns 1,710 shares of the medical equipment provider's stock worth $31,000 after acquiring an additional 1,269 shares during the period. Arax Advisory Partners boosted its position in shares of AxoGen by 362.4% during the 4th quarter. Arax Advisory Partners now owns 1,045 shares of the medical equipment provider's stock valued at $34,000 after acquiring an additional 819 shares in the last quarter. Finally, Caitong International Asset Management Co. Ltd acquired a new stake in shares of AxoGen during the 4th quarter valued at about $36,000. Institutional investors and hedge funds own 80.29% of the company's stock.
About AxoGen
(
Get Free Report)
AxoGen, Inc is a Florida-based medical technology company that develops and commercializes surgical solutions for peripheral nerve damage. Founded in 2002 and headquartered in Alachua, Florida, the company focuses on restoring nerve function and improving patient outcomes through innovative biologic and engineered products. AxoGen's offerings address a range of traumatic and iatrogenic injuries, offering alternatives to traditional nerve autografts.
The company's core product portfolio includes the Avance® Nerve Graft, a decellularized human nerve allograft designed to bridge nerve gaps without the need for a secondary harvest site, and the Axoguard® Nerve Connector and Protector devices, which facilitate nerve coaptation and protect repaired sites from surrounding scar tissue.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
